Skip to main content
Clinical Trials/NCT05958290
NCT05958290
Recruiting
N/A

Cardiac Implantable Electronic Device Lifelong Antibiotic thErapy vs Stop and See The CIEDLESS Study A Prospective Study

Rigshospitalet, Denmark1 site in 1 country90 target enrollmentSeptember 1, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiac Implantable Electronic Device Infection
Sponsor
Rigshospitalet, Denmark
Enrollment
90
Locations
1
Primary Endpoint
Composite endpoint of death or relapse bacteremia
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The goal of this non-randomized prospective study is to test whether 6-weeks antibiotic treatment can cure an cardiac implantable electronic device (CIED) infection in patients where device extraction is not feasible.

The main question it aims to answer:

• Is 6-weeks medical therapy effective in curing definite CIED infection with device retention?

Participants will discontinue the antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total. After discontinuation of antibiotics, patients are closely observed for bacterial relapse.

For patients who are not interested in participation and who do not have exclusion criteria, we will ask for consent into a registry as we wish to compare patients undergoing discontinuation of antibiotics with patients undergoing standard treatment.

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
November 30, 2026
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emil Loldrup Fosbol

Professor

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Definite CIED infection by the EHRA criteria
  • Deemed non-eligible for CIED extraction

Exclusion Criteria

  • Unavailable for follow-up (e.g., tourist)

Outcomes

Primary Outcomes

Composite endpoint of death or relapse bacteremia

Time Frame: 12 months

Composite endpoint of all-cause mortality or relapse bacteremia with the primary pathogen

Secondary Outcomes

  • Death(12 months)
  • Device extraction(12 months)
  • Readmission for any cause(12 months)
  • Change in quality of life(12 months)

Study Sites (1)

Loading locations...

Similar Trials